You BH et al., HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2, , Proc Natl Acad Sci U S A., Dec 03, 2019 ➔

Gentile ME et al., NK cell recruitment limits tissue damage during an enteric helminth infection , , Mucosal Immunol., Nov 27, 2019 ➔

Steinmann S et al., DAPK1 loss triggers tumor invasion in colorectal tumor cells., , Cell Death Dis, Nov 26, 2019 ➔

Barrow-McGee R et al., Real‐time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study, , J Pathol., Nov 22, 2019 ➔

Oliver AJ et al., Tissue‐specific tumor microenvironments influence responses to immunotherapies., , Clin Transl Immunology, Nov 21, 2019 ➔

Chan SL et al., Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma, , Liver Cancer, Nov 21, 2019 ➔

He D et al., Whole blood vs PBMC: compartmental differences in gene expression profiling exemplified in asthma, , Allergy Asthma Clin Immunol., Nov 21, 2019 ➔

Fong L et al., Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer, , Cancer Discovery, Nov 15, 2019 ➔

Long Y et al., Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma, , Cancer Res, Nov 13, 2019 ➔

Mairinger F et al., Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response., , Cancer Manag Res., Nov 12, 2019 ➔

Warchal SJ et al., High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways, , Bioorg Med Chem., Nov 09, 2019 ➔

Lee JS et al., Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer., , Breast Cancer Res, Nov 08, 2019 ➔

Ihle CL et al., Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients., , J Immunother Cancer, Nov 08, 2019 ➔

Mahalingam D et al., Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a Phase 1b study, , Clin Cancer Res, Nov 06, 2019 ➔

Damotte D et al., The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort., , J Transl Med., Nov 04, 2019 ➔